
ANI Pharma (ANIP) Stock Forecast & Price Target
ANI Pharma (ANIP) Analyst Ratings
Bulls say
ANI Pharmaceuticals Inc. is poised for significant financial growth, evidenced by a projected increase in adjusted operating margin from 25.4% in 2024 to 29.7% by 2028, alongside anticipated operating cash flow exceeding $630 million from 2025 to 2028. The company demonstrated resilience with fourth-quarter results reflecting consecutive top and bottom-line growth, and has adjusted its FY 2025 revenue estimate upward to $269.5 million, aligning with the new guidance range. Furthermore, the launch of exclusive generic products and a rising demand in the ACTH gel market are contributing to a strong outlook, signaling an optimistic growth trajectory moving into 2025.
Bears say
ANI Pharmaceuticals has experienced significant revenue declines in its Brands segment during the second and third quarters of 2024 due to shifting market conditions for certain products, particularly Cortrophin, which has encountered recurring pricing pressures during the first quarter. Management has acknowledged ongoing challenges, including decreased market access linked to inadequate funding from non-profit foundations for Medicare co-pays in 2025, which may further hinder revenue stability. Although recent quarterly results reflected total revenue exceeding expectations, the forecast indicates a substantial anticipated drop in revenues for the first quarter of 2025, raising concerns about long-term performance and sustainability in the face of these ongoing market issues.
This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.
ANI Pharma (ANIP) Analyst Forecast & Price Prediction
Start investing in ANI Pharma (ANIP)
Order type
Buy in
Order amount
Est. shares
0 shares